Evercore ISI upgraded shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) from an in-line rating to an outperform rating in a research report released on Monday morning, MarketBeat Ratings reports.

A number of other equities analysts have also commented on the company. Zacks Investment Research lowered Ultragenyx Pharmaceutical from a hold rating to a sell rating in a research note on Wednesday, October 25th. JPMorgan Chase & Co. restated a buy rating and set a $76.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Sunday, November 5th. Robert W. Baird lowered their price objective on Ultragenyx Pharmaceutical from $85.00 to $80.00 and set an outperform rating on the stock in a research note on Friday, November 3rd. Cowen restated a buy rating on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, November 15th. Finally, Jefferies Group upgraded Ultragenyx Pharmaceutical from a hold rating to a buy rating and raised their price objective for the stock from $58.00 to $72.00 in a research note on Monday, December 4th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have issued a buy rating to the company’s stock. Ultragenyx Pharmaceutical has a consensus rating of Hold and a consensus target price of $72.06.

Ultragenyx Pharmaceutical (RARE) traded up $4.23 during trading on Monday, reaching $53.39. The company’s stock had a trading volume of 1,025,200 shares, compared to its average volume of 476,843. Ultragenyx Pharmaceutical has a 12-month low of $43.14 and a 12-month high of $91.35. The company has a market cap of $2,480.00, a price-to-earnings ratio of -7.66 and a beta of 1.83.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.87) EPS for the quarter, hitting the Zacks’ consensus estimate of ($1.87). The company had revenue of $0.20 million for the quarter, compared to the consensus estimate of $0.02 million. During the same quarter last year, the business earned ($1.64) EPS. Ultragenyx Pharmaceutical’s revenue was up 81.8% on a year-over-year basis. equities analysts anticipate that Ultragenyx Pharmaceutical will post -7.31 earnings per share for the current year.

Several institutional investors and hedge funds have recently modified their holdings of RARE. Schwab Charles Investment Management Inc. increased its stake in shares of Ultragenyx Pharmaceutical by 3.6% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 219,415 shares of the biopharmaceutical company’s stock valued at $13,628,000 after purchasing an additional 7,618 shares during the last quarter. Legal & General Group Plc increased its stake in shares of Ultragenyx Pharmaceutical by 17.2% in the 2nd quarter. Legal & General Group Plc now owns 15,082 shares of the biopharmaceutical company’s stock valued at $933,000 after purchasing an additional 2,212 shares during the last quarter. Prudential Financial Inc. increased its stake in shares of Ultragenyx Pharmaceutical by 85.0% in the 2nd quarter. Prudential Financial Inc. now owns 6,770 shares of the biopharmaceutical company’s stock valued at $420,000 after purchasing an additional 3,110 shares during the last quarter. Principal Financial Group Inc. increased its stake in shares of Ultragenyx Pharmaceutical by 1.0% in the 2nd quarter. Principal Financial Group Inc. now owns 73,412 shares of the biopharmaceutical company’s stock valued at $4,559,000 after purchasing an additional 722 shares during the last quarter. Finally, Teachers Advisors LLC increased its stake in shares of Ultragenyx Pharmaceutical by 3.7% in the 2nd quarter. Teachers Advisors LLC now owns 169,886 shares of the biopharmaceutical company’s stock valued at $10,552,000 after purchasing an additional 5,988 shares during the last quarter. Institutional investors own 94.10% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Ultragenyx Pharmaceutical (RARE) Upgraded at Evercore ISI” was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.dailypolitical.com/2018/01/23/ultragenyx-pharmaceutical-rare-upgraded-at-evercore-isi.html.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.